Equity Overview
Price & Market Data
Price: $1.90
Daily Change: -$0.01 / 0.53%
Range: $1.83 - $1.97
Market Cap: $131,981,136
Volume: 458,793
Performance Metrics
1 Week: -2.11%
1 Month: -0.53%
3 Months: 12.05%
6 Months: -25.30%
1 Year: -71.38%
YTD: -25.30%
Company Details
Employees: 157
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.